Literature DB >> 26517583

MsFLASH participants' priorities for alleviating menopausal symptoms.

J S Carpenter1, N F Woods2, J L Otte1, K A Guthrie3, C Hohensee3, K M Newton4, H Joffe5, L Cohen6, B Sternfeld7, R J Lau8, S D Reed9, A Z LaCroix10.   

Abstract

OBJECTIVE: To describe self-reported menopausal symptom priorities and their association with demographics and other symptoms among participants in an intervention trial for vasomotor symptoms (VMS).
METHODS: Cross-sectional study embedded in the MsFLASH 02 trial, a three-by-two factorial design of yoga vs. exercise vs. usual activity and omega-3-fatty acid vs. placebo. At baseline, women (n = 354) completed hot flush diaries, a card sort task to prioritize symptoms they would most like to alleviate, and standardized questionnaires.
RESULTS: The most common symptom priorities were: VMS (n = 322), sleep (n = 191), concentration (n = 140), and fatigue (n = 116). In multivariate models, women who chose VMS as their top priority symptom (n = 210) reported significantly greater VMS severity (p = 0.004) and never smoking (p = 0.012), and women who chose sleep as their top priority symptom (n = 100) were more educated (p ≤ 0.001) and had worse sleep quality (p < 0.001). ROC curves identified sleep scale scores that were highly predictive of ranking sleep as a top priority symptom.
CONCLUSIONS: Among women entering an intervention trial for VMS and with relatively low prevalence of depression and anxiety, VMS was the priority symptom for treatment. A card sort may be a valid tool for quickly assessing symptom priorities in clinical practice and research.

Entities:  

Keywords:  COGNITIVE FUNCTIONING; FATIGUE; MENOPAUSE; SLEEP DISTURBANCES; SYMPTOMS; VASOMOTOR SYMPTOMS

Mesh:

Substances:

Year:  2015        PMID: 26517583      PMCID: PMC4732703          DOI: 10.3109/13697137.2015.1083003

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.024


  30 in total

1.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

2.  Symptom clusters during the late reproductive stage through the early postmenopause: observations from the Seattle Midlife Women's Health Study.

Authors:  Lori A Cray; Nancy Fugate Woods; Jerald R Herting; Ellen Sullivan Mitchell
Journal:  Menopause       Date:  2012-08       Impact factor: 2.953

Review 3.  The sleep of African Americans: a comparative review.

Authors:  H Heith Durrence; Kenneth L Lichstein
Journal:  Behav Sleep Med       Date:  2006       Impact factor: 2.964

4.  Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives.

Authors:  Nancy Fugate Woods; Ellen Sullivan Mitchell
Journal:  Am J Med       Date:  2005-12-19       Impact factor: 4.965

Review 5.  The middle-range theory of unpleasant symptoms: an update.

Authors:  E R Lenz; L C Pugh; R A Milligan; A Gift; F Suppe
Journal:  ANS Adv Nurs Sci       Date:  1997-03       Impact factor: 1.824

6.  Application of person-centered analytic methodology in longitudinal research: exemplars from the Women's Health Initiative Clinical Trial data.

Authors:  Oleg Zaslavsky; Barbara B Cochrane; Jerald R Herting; Hilaire J Thompson; Nancy F Woods; Andrea Lacroix
Journal:  Res Nurs Health       Date:  2013-12-11       Impact factor: 2.228

7.  Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age.

Authors:  E B Gold; B Sternfeld; J L Kelsey; C Brown; C Mouton; N Reame; L Salamone; R Stellato
Journal:  Am J Epidemiol       Date:  2000-09-01       Impact factor: 4.897

8.  Cognitive symptoms during the menopausal transition and early postmenopause.

Authors:  E S Mitchell; N F Woods
Journal:  Climacteric       Date:  2011-04       Impact factor: 3.005

9.  Objective hot flashes are negatively related to verbal memory performance in midlife women.

Authors:  Pauline M Maki; Lauren L Drogos; Leah H Rubin; Suzanne Banuvar; Lee P Shulman; Stacie E Geller
Journal:  Menopause       Date:  2008 Sep-Oct       Impact factor: 2.953

Review 10.  Effects of mind-body therapies on symptom clusters during the menopausal transition.

Authors:  N F Woods; E S Mitchell; J G Schnall; L Cray; R Ismail; L Taylor-Swanson; A Thomas
Journal:  Climacteric       Date:  2013-10-29       Impact factor: 3.005

View more
  12 in total

Review 1.  Improving vasomotor symptoms; psychological symptoms; and health-related quality of life in peri- or post-menopausal women through yoga: An umbrella systematic review and meta-analysis.

Authors:  M Shepherd-Banigan; K M Goldstein; R R Coeytaux; J R McDuffie; A P Goode; A S Kosinski; M G Van Noord; D Befus; S Adam; V Masilamani; A Nagi; J W Williams
Journal:  Complement Ther Med       Date:  2017-08-24       Impact factor: 2.446

2.  Factors associated with sexual quality of life among midlife women in Serbia.

Authors:  Tatjana Gazibara; Selmina Nurkovic; Nikolina Kovacevic; Ilma Kurtagic; Biljana Rancic; Sanja Radovanovic; Branislav Milosevic; Milan Terzic; Jelena Dotlic
Journal:  Qual Life Res       Date:  2017-06-03       Impact factor: 4.147

Review 3.  Lights on MsFLASH: a review of contributions.

Authors:  Susan D Reed; Andrea Z LaCroix; Garnet L Anderson; Kristine E Ensrud; Bette Caan; Janet S Carpenter; Lee Cohen; Susan J Diem; Ellen W Freeman; Hadine Joffe; Joseph C Larson; Susan M McCurry; Caroline M Mitchell; Katherine M Newton; Barbara Sternfeld; Katherine A Guthrie
Journal:  Menopause       Date:  2020-04       Impact factor: 2.953

4.  Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales.

Authors:  Janet S Carpenter; Giorgos Bakoyannis; Julie L Otte; Chen X Chen; Kevin L Rand; Nancy Woods; Katherine Newton; Hadine Joffe; JoAnn E Manson; Ellen W Freeman; Katherine A Guthrie
Journal:  Menopause       Date:  2017-08       Impact factor: 3.310

5.  Treating hot flushes with a neurokinin 3 receptor antagonist.

Authors:  Julia K Prague; Waljit S Dhillo
Journal:  Oncotarget       Date:  2017-11-11

6.  Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Julia K Prague; Rachel E Roberts; Alexander N Comninos; Sophie Clarke; Channa N Jayasena; Zachary Nash; Chedie Doyle; Deborah A Papadopoulou; Stephen R Bloom; Pharis Mohideen; Nicholas Panay; Myra S Hunter; Johannes D Veldhuis; Lorraine C Webber; Les Huson; Waljit S Dhillo
Journal:  Lancet       Date:  2017-04-03       Impact factor: 79.321

7.  Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action.

Authors:  Julia K Prague; Rachel E Roberts; Alexander N Comninos; Sophie Clarke; Channa N Jayasena; Pharis Mohideen; Vivian H Lin; Theresa P Stern; Nicholas Panay; Myra S Hunter; Lorraine C Webber; Waljit S Dhillo
Journal:  Menopause       Date:  2018-08       Impact factor: 2.953

8.  Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women.

Authors:  Julia K Prague; Ali Abbara; Alexander N Comninos; Channa N Jayasena; Claire E Higham; Jo Adaway; Brian G Keevil; Johannes D Veldhuis; Waljit S Dhillo
Journal:  J Endocr Soc       Date:  2019-11-14

9.  Female Sexual Function Index Short Version: A MsFLASH Item Response Analysis.

Authors:  Janet S Carpenter; Salene M W Jones; Christina R Studts; Julia R Heiman; Susan D Reed; Katherine M Newton; Katherine A Guthrie; Joseph C Larson; Lee S Cohen; Ellen W Freeman; R Jane Lau; Lee A Learman; Jan L Shifren
Journal:  Arch Sex Behav       Date:  2016-08-08

Review 10.  Consequences of premature ovarian insufficiency on women's sexual health.

Authors:  Marzena Maciejewska-Jeske; Anna Szeliga; Błażej Męczekalski
Journal:  Prz Menopauzalny       Date:  2018-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.